Anavex Life Sciences Corp (AVXL)

[frrol]

Let's see what Monday brings. Like trial results, this is the kind of development that really needs a thorough and frank explanation to investors. Missling is inclined to spin, so others like Talavera, Sabbagh, or Grimmer should join. Jin would also be great, particularly if there were data issues or analysis disagreements.

Missling will hopefully be replaced. If 2-73 is a viable drug, we shouldn't be sitting here in 2025 with no trials and no approvals. He ultimately failed, and made pretty foolish mistakes along the way. Better would be selling the company to a large pharma with stronger management and adequate capital.